After Sarepta (SRPT) Therapeutics shared the first clinical results from two of its siRNA programs for neuromuscular diseases, Leerink analyst Joseph Schwartz said the initial siRNA data in DM1 and FSHD are “a bit of a mixed bag.” While it seems like they can achieve “impressive” muscle concentration, and the DUX-4 reduction looks good, the DM1 data are “very limited and safety remains an open debate,” says the analyst, who has a Market Perform rating on Sarepta shares.
Claim 30% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta early DM1 data ‘appear promising,’ says Oppenheimer
- Sarepta announces first clinical data from pipeline targeting FSHD1, DM1
- Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential
- Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
- Sarepta provides regulatory update on Amondys 45, Vyondys 53